Supplementary Fig. 2. Verification of variations in PNPLA3, TM6SF2, and AGXT2 in a cohort of 120 MASLD patients. (A) Pie charts showing the proportion of MASLD samples collected for this study with genetic alterations in MASLD-associated genes: rs-738409 in PNPLA3, rs58542926 in TM6SF2, and rs2291702 in AGXT2. Stacked bar charts showing the proportion of each specific genotype in the altered groups.

(B) Boxplot indicating normalized gene expression levels for specific genotypes at the altered sites. Significant differences are indicated between homologous alterations of PNPLA3, TM6SF2, and AGXT2 from CC to GG, from CC to TT, and from TT to CC, respectively. (C) Boxplot showing normalized gene expression levels according to altered status and stage of MASLD progression. Gene expression levels were compared in unaltered groups and altered groups in steatosis and MASH patient samples (P-values are estimated by Students’ t-test, “alt=less”. Red squares indicate the mean expression level in each individual group).